TICKERNERD
Menu
MIRMMIRMHealthcare · Biotechnology

MIRM Stock Forecast: Mirum Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$98
−2.38% on the day

The 14 Wall Street analysts covering Mirum Pharmaceuticals, Inc. hold a median 12-month price target of $137 — +39.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$6.4B
Ticker Nerd rank
67 / 100
Median analyst target
$137
Analysts covering
14
Revenue$176.2M+37.9% y/y
Operating income−$26.1M
Net income−$67.2M
Free cash flow−$69.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.4%
1M
−0.0%
YTD
+24.3%
1Y
+29.3%
From 52W high
−23.6%
From 52W low
+53.2%
$64
$129
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MIRM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Mirum Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
67 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
91
Momentum
86
Value
81
Revisions
78
Accruals
69
Quality
60
Growth
39
Size
20
Issuance
7

Volatility (91): The share price has been relatively steady.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MIRM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MIRM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200Oct 25Jan 26Apr 26Jul 26MIRMHigh $183Median $137Low $118

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
14 Buy0 Hold0 Sell
Low $118Median $137High $183

The green dot is the last close — the median target sits +39.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
27 Aug 2026CitizensReiteratesMarket Outperform$137
6 Aug 2026CitizensMaintainsMarket Outperform$146 → $137
6 Aug 2026CitizensMaintainsMarket Outperform—
6 Aug 2026HC Wainwright & Co.MaintainsBuy—
6 Aug 2026HC Wainwright & Co.MaintainsBuy$185 → $140
6 Aug 2026RBC CapitalMaintainsOutperform—
6 Aug 2026RBC CapitalMaintainsOutperform$148 → $135
6 Aug 2026TD CowenMaintainsBuy—
6 Aug 2026TD CowenMaintainsBuy$145 → $140
7 July 2026RBC CapitalMaintainsOutperform$142 → $148
7 July 2026RBC CapitalMaintainsOutperform—
2 July 2026JP MorganMaintainsOverweight—
2 July 2026JP MorganMaintainsOverweight$115 → $125
15 June 2026CitizensMaintainsMarket Outperform—
11 June 2026Morgan StanleyMaintainsOverweight—
2 June 2026CitigroupInitiatesBuy—
19 May 2026Wolfe ResearchInitiatesOutperform—
7 May 2026BairdMaintainsOutperform—
7 May 2026Evercore ISI GroupMaintainsOutperform—
7 May 2026RBC CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MIRM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MIRM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Mirum Pharmaceuticals, Inc. returned +29.3% against +17.5% for the S&P 500, dividends included.

MIRM vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Oct 25Jan 26Apr 26Jul 26MIRMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MIRM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Mirum Pharmaceuticals, Inc. (MIRM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−208.9×

Cheaper than 99% of US stocks

Price / sales
10.3×

Cheaper than 14% of US stocks

Price / book
−597.1×

Cheaper than 99% of US stocks

EV / EBITDA
−95.4×

Cheaper than 96% of US stocks

Growth & margins
Revenue growth (YoY)
37.9%

Higher than 82% of US stocks

Earnings growth (YoY)
37.9%

Higher than 70% of US stocks

Gross margin
82.8%

Higher than 93% of US stocks

Operating margin
−14.8%

Higher than 23% of US stocks

Net margin
−139.2%

Higher than 4% of US stocks

Returns & dividend
Return on equity
−703.0%

Higher than 2% of US stocks

Return on assets
−6.8%

Higher than 29% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Mirum Pharmaceuticals, Inc. (MIRM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Mirum Pharmaceuticals, Inc. has a market value of $6.4B and an enterprise value of $6.7B.

  • Revenue in the twelve months to 30 June 2026: $618.1M. The latest quarter grew 37.9% year on year.

  • Net income over the same four quarters: −$860.2M, a −139.2% net margin.

  • Diluted earnings per share, trailing twelve months: $−14.55.

  • Free cash flow in the twelve months to 30 June 2026: −$263.7M.

  • Shares outstanding: 64.8M.

  • Trailing P/E: −208.9×; forward P/E: −283.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Mirum Pharmaceuticals, Inc. employs 433 people — $1.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

MIRM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MIRMMirum Pharmaceuticals, Inc.$6.4B
67
CGONCG Oncology, Inc.$6.4B
17
TVTXTravere Therapeutics, Inc.$6.2B
87
ORKAOruka Therapeutics, Inc.$6.1B
40
SRRKScholar Rock Holding Corp.$6.7B
37
CAICaris Life Sciences, Inc.$6.9B
32
DNTHDianthus Therapeutics, Inc.$5.8B
61

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Mirum Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MIRM news & analysis

Mirum Pharmaceuticals, Inc. (MIRM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 10 Sept 2026neutral

Mirum Pharmaceuticals presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the event published by Seeking Alpha. The presentation was part of the company's participation in a major industry investor conference.

Why it matters — MIRM watchers would care because the presentation offers direct insight from company leadership at a prominent biopharma investor summit, which can signal the company's strategic priorities and messaging to the investment community.

Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer

Business Wire · 8 Sept 2026positive

Mirum Pharmaceuticals announced the appointment of Dr. Rob Myers as Chief Medical Officer. The appointment was announced in a press release from the company's headquarters in Foster City, California.

Why it matters — MIRM watchers would care because Dr. Myers will oversee the company's medical and clinical development functions, a leadership role central to advancing its pipeline.

Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report?

Zacks Investment Research · 4 Sept 2026positive

Mirum Pharmaceuticals reported earnings 30 days ago, and its stock has risen 6.9% since the release. The report examines what may be next for the company following that earnings announcement.

Why it matters — This report provides an update on MIRM's share price performance in the month following its recent earnings release, which is relevant for investors tracking the company's momentum.

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Business Wire · 2 Sept 2026neutral

Mirum Pharmaceuticals announced that it will participate in upcoming investor conferences, as reported by Business Wire from its Foster City, California headquarters.

Why it matters — MIRM watchers would care because participation in investor conferences provides opportunities for the company to present its business to the investment community.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 11 Aug 2026neutral

Mirum Pharmaceuticals announced it has issued inducement grants under Nasdaq Listing Rule 5635(c)(4). The grants were made to new employees as an inducement to join the company.

Why it matters — MIRM watchers would note this as a standard corporate practice for attracting new talent, which could signal hiring momentum but does not directly impact near-term financials.

FAQ

Frequently asked questions about MIRM stock

What is the MIRM stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Mirum Pharmaceuticals, Inc. have a median 12-month price target of $137, with estimates ranging from $118 to $183. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MIRM stock a buy right now?

Of the 14 analysts covering Mirum Pharmaceuticals, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Mirum Pharmaceuticals, Inc. 67 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MIRM?

As at 12 Sept 2026, Mirum Pharmaceuticals, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (91 of 100).

Will MIRM stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +39.5% from the last close, and Ticker Nerd's factor model ranks Mirum Pharmaceuticals, Inc. 67 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MIRM stock forecast for 2030?

No analyst covering Mirum Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MIRM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $118 to $183 over the next 12 months.

How has MIRM stock performed over the past year?

Mirum Pharmaceuticals, Inc. returned +29.3% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Mirum Pharmaceuticals, Inc. do?

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on rare and orphan diseases, with particular strength in liver and bile-acid related disorders.

What is the latest news on MIRM?

The most recent item we track (Seeking Alpha, 10 Sept 2026): "Mirum Pharmaceuticals, Inc. (MIRM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript". Mirum Pharmaceuticals presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the event published by Seeking Alpha. The presentation was part of the company's participation in a major industry investor conference.

Company

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on rare and orphan diseases, with particular strength in liver and bile-acid related disorders. The company develops and commercializes approved medicines and investigational therapies designed for patients with serious conditions that have limited treatment options. Its commercial portfolio includes treatments for Alagille syndrome, progressive familial intrahepatic cholestasis, bile-acid synthesis disorders, and cerebrotendinous xanthomatosis, supported by a pipeline of additional rare-disease programs. Mirum operates as a specialty rare-disease company, combining drug development, regulatory expertise, and patient-support capabilities to serve children, adults, and families affected by complex genetic and metabolic conditions. Headquartered in Foster City, California, Mirum Pharmaceuticals plays a focused role in the global rare-disease market by bringing targeted therapies to highly specialized clinical settings.

CEO Mr. Christopher Peetz · 433 employees · United States · https://www.mirumpharma.com